Reasons for discontinuation of GLP1 receptor agonists: Data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity

Volumn 10, Issue , 2017, Pages 403-412

  Sikirica, Mirko V ^a   Martin, Alan A ^b   Wood, Robert ^c   Leith, Andrea ^c   Piercy, James ^c   Higgins, Victoria ^c  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Antidiabetic drug; Cross sectional survey; Discontinuation; Glycemic control; Incretin therapy; Incretins

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL DECISION MAKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG COST; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATIENT PREFERENCE; PERSONAL EXPERIENCE; PHYSICIAN ATTITUDE; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL; VOMITING; WEIGHT GAIN;

EID: 85032856532     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s141235     Document Type: Article

References (26)

1. World Health Organization. Global Report on Diabetes. 2016. Geneva: WHO; 2016.
2. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2016;39(Suppl 1):S52-S59.
3. Davidson JA. Incretin-based therapies: focus on effects beyond glycemic control alone. Diabetes Ther. 2013;4(2):221-238.
4. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25(3):777-786.
5. Divino V, DeKoven M, Hallinan S, et al. Glucagon-like peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. Diabetes Ther. 2014;5(2):499-520.
6. Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119-1133.
7. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Realworld physician and patient behaviour across countries: diseasespecific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063-3072.
8. Wood R, Paoli CJ, Hays RD, Taylor-Stokes G, Piercy J, Gitlin M. Evaluation of the consumer assessment of healthcare providers and systems in-center hemodialysis survey. Clin J Am Soc Nephrol. 2014;9(6):1099-1108.
9. Rodriguez MR, Small M, Fermer S, Bailey J, Wood R, Fink-Wagner AH. Real world burden of COPD: employed vs not in paid employment patients. J Health Prod. 2013;7(1):29-44.
10. Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.
11. Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371-380.
12. Atun RA, Lennox-Chhugani N, Drobniewski F, Samyshkin YA, Coker RJ. A framework and toolkit for capturing the communicable disease programmes within health systems: tuberculosis control as an illustrative example. Eur J Public Health. 2004;14(3):267-273.
13. European Pharmaceutical Market Research Association. Code of Conduct. Available from: http://www.ephmra.org/code-of-conduct/157/. Accessed January 18, 2017.
14. Department of Health and Human Services. Summary of the HIPAA privacy rule. 2016. Available from: https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html. Accessed January 18, 2017.
15. Market Research Society. The Data Protection Act 1998 and market research: guidance for MRS members. 2003. Available from: https://www.mrs.org.uk/pdf/The%20Data%20Protection%20Act%201998%20and%20Market%20Research.pdf. Accessed January 18, 2017.
16. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11(4):338-342.
17. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010;122(2):112-120.
18. Sanyal D, Majumdar A. Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting. Indian J Endocrinol Metab. 2013;17(Suppl 1):S301-S303.
19. Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 2014;16(8):673-688.
20. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19-28.
21. Porcellati F, Lucidi P, Bolli GB, Fanelli CG. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes Metab. 2015;41(6 Suppl 1): 6S16-6S20.
22. Elliott L, Fidler C, Ditchfield A, Stissing T. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7(1):45-60.
23. Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management - reflections from a diabetes care editors’ expert forum. Diabetes Care. 2014;37(9):2647-2659.
24. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
25. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
26. Saunders C, Byrne CD, Guthrie B, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30(3):300-308.